Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M V Relling

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
Clinical Pharmacology and Therapeutics|June 1, 1987
Simultaneous administration of multiple model substrates to assess hepatic drug clearanceW R Crom, S L Webster, L Bobo, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in childrenW E Evans, M V Relling, W P Petros, et al.
Journal of Immunological Methods|May 24, 2000
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemiaB Wang, L J Hak, M V Relling, et al.
Annals of Hematology|May 6, 2004
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemiaC H Pui, M V Relling, J T Sandlund, et al.
Cancer Research|August 2, 2001
Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cellsT Dervieux, J G Blanco, E Y Krynetski, et al.
Clinical Pharmacology and Therapeutics|September 1, 1991
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjectsM V Relling, J Cherrie, M J Schell, et al.
American Journal of Clinical Oncology|December 1, 1991
Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumorsC B Pratt, M V Relling, W H Meyer, et al.
The Journal of Clinical Investigation|May 1, 1993
Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black AmericansW E Evans, M V Relling, A Rahman, et al.
Clinical Pharmacology and Therapeutics|August 8, 1998
Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humansT Loennechen, C R Yates, M Y Fessing, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 1995
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferaseE Y Krynetski, J D Schuetz, A J Galpin, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
Clinical Pharmacology and Therapeutics|June 1, 1987
Simultaneous administration of multiple model substrates to assess hepatic drug clearanceW R Crom, S L Webster, L Bobo, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in childrenW E Evans, M V Relling, W P Petros, et al.
Journal of Immunological Methods|May 24, 2000
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemiaB Wang, L J Hak, M V Relling, et al.
Annals of Hematology|May 6, 2004
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemiaC H Pui, M V Relling, J T Sandlund, et al.
Cancer Research|August 2, 2001
Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cellsT Dervieux, J G Blanco, E Y Krynetski, et al.
Clinical Pharmacology and Therapeutics|September 1, 1991
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjectsM V Relling, J Cherrie, M J Schell, et al.
American Journal of Clinical Oncology|December 1, 1991
Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumorsC B Pratt, M V Relling, W H Meyer, et al.
The Journal of Clinical Investigation|May 1, 1993
Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black AmericansW E Evans, M V Relling, A Rahman, et al.
Clinical Pharmacology and Therapeutics|August 8, 1998
Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humansT Loennechen, C R Yates, M Y Fessing, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 1995
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferaseE Y Krynetski, J D Schuetz, A J Galpin, et al.
Pageof 18